Nascent Biotech, Inc.
NBIO
$0.0007
-$0.0001-12.50%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 30.14% | 1.06% | 75.47% | -469.32% | 58.44% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -100.66% | -96.81% | -52.65% | 258.09% |
| Total Other Non-Cash Items | 164.22% | 141.54% | -69.17% | 164.60% | -108.94% |
| Change in Net Operating Assets | -101.46% | -28.00% | 84.24% | -165.52% | 375.56% |
| Cash from Operations | -99.57% | 9.03% | 47.02% | 21.26% | 52.68% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 63.64% | -- |
| Issuance of Common Stock | -- | -- | -- | 2,293.33% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -9.12% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -99.57% | 34.89% | 39.00% | -4.03% | -417.77% |